About Us

An innovative biopharmaceutical company,

integrating antibody drug development, production and commercialization.

Established in December 2016, AD Pharmaceuticals Co., Ltd. (AD Pharmaceuticals) is a subsidiary of Akeso, Inc. (9926.HK), the pioneer in biologics innovation in China. AD Pharmaceuticals is an innovative biopharmaceutical company integrating antibody drug development, production and commercialization.

Adhering to the concept of patient-centered and clinical value-oriented innovative drug development, AD Pharmaceuticals remains on the frontiers of technology and focuses on the innovation and development of innovative drugs and combined therapies for cardiovascular disease, tumors and other major diseases. At present, the Company has two products under clinical development with independent intellectual property rights, namely Ebronucimab (R&D code: AK102), a novel PCSK9 monoclonal antibody, and Pulocimab (R&D code: AK109), a VEGFR-2 monoclonal antibody.

AD Pharmaceuticals fully integrates and utilizes its superior resources to efficiently promote the global development and commercialization of innovative drugs. We expect to make a real and meaningful difference in the lives of patients around the world through the continuous R&D, production and commercialization of innovative drugs, and the development of high-quality innovative biological drugs.

-Established in

2016

-Subsidiary of

Akeso, Inc. (9926.HK)

Milestones

2024

February
Akeso, Inc.(9926.HK) and Dawnrays Pharmaceutical entered into the Equity Transfer Agreement, AD Pharmaceuticals became an indirect wholly-owned subsidiary of Akeso.
August
Phase IIl clinical results of Ebronucimab in Chinese patients with hypercholesterolemia were published at the 《Pharmacological Research》.

2023

May
Phase IIl clinical results of Ebronucimab were published at the European Atherosclerosis Society (EAS 2023) .
June
NMPA accepted Ebronucimab (PCSK9) marketing application in two indications：1) primary hypercholesterolemia and mixed hyperlipidemia； 2) heterozygous familial hypercholesterolemia (HeFH).

2022

November
Phase II clinical results of Ebronucimab in the treatment of Hyperlipidemia were published in a poster session at AHA Scientific Sessions 2022.

The rigistry Phase III clinical trial of Ebronucimab in the treatment of primary hypercholesterolemia patients reached its primary endpoint.
July
Patient enrollment was completed in the registered clinical study of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.
May
AD Pharmaceuticals Puts China-Singapore Guangzhou Knowledge City Base into Operation.
April
The first-in-human, Phase I clinical study of Pulocimab in the treatment of patients with advanced or metastatic solid tumors was presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in a poster session.

2021

December
Enrollment was completed ahead of schedule for a pivotal Phase III clinical trial for registration purposes of Ebronucimab in the treatment of primary hypercholesterolemia and mixed hyperlipidemia.
September
A phase II clinical study of Ebronucimab in the treatment of hypercholesterolemia patients at extremely high risk or high risk for cardiovascular disease reached its primary endpoint.
August
A phase Ib/II clinical study of Pulocimab combined with Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) in the treatment of advanced solid tumors was approved in China.
July
A phase Ib/II clinical study of Pulocimab combined with Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) for the treatment of advanced gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction was approved in China.

2020

December
Enrollment was completed ahead of schedule for a Phase IIb clinical trial of Ebronucimab in the treatment of high-risk/extremely high-risk hypercholesterolemia.
June
Enrollment was completed for a Phase I clinical trial of Pulocimab in the treatment of advanced solid tumors.

2019

May

The first patient was enrolled in a Phase II clinical trial of Ebronucimab in the treatment of heterozygous familial hypercholesterolemia.

2018

November
Pulocimab was first approved for clinical trials in China for the treatment of solid tumors.
March
Ebronucimab was first approved for clinical trials in China for the treatment of hyperlipidemia.

2016

December

AD Pharmaceuticals was established as a joint venture between Akeso, Inc. (9926.HK) and Dawnrays Pharmaceutical (2348.HK), initialized by Dr. Michelle Xia and Dr. Kehan Xu.